Galvokimig: Multispecific Antibody Design Targeting IL‑13 & IL‑17A/F & Insights from Early Clinical Studies
- Balancing folding, stability, and affinity across dual binding arms to enable robust and consistent target engagement
- Designing architectures that minimise steric interference while preserving full dual-target functionality
- Accelerating early optimisation and decision-making to shorten timelines from discovery to clinical candidate